GlobeNewswire: Bavarian Nordic A/S Contains the last 10 of 1700 releaseshttp://www.globenewswire.com/External?Length=42024-03-19T08:09:20ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/13/2845416/0/en/Bavarian-Nordic-Receives-Approval-of-Smallpox-and-Mpox-Vaccine-in-Switzerland.html?f=22&fvtc=4&fvtv=8929Bavarian Nordic Receives Approval of Smallpox and Mpox Vaccine in Switzerland2024-03-13T12:29:21Z<![CDATA[COPENHAGEN, Denmark, March 13, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Swiss Agency for Therapeutic Products, Swissmedic, has approved JYNNEOS® (MVA-BN) for active immunization against disease caused by smallpox, mpox and vaccinia viruses in adults 18 years of age and older.]]>https://www.globenewswire.com/news-release/2024/03/13/2845416/0/da/Bavarian-Nordics-mpox-og-koppevaccine-opn%C3%A5r-godkendelse-i-Schweiz.html?f=22&fvtc=4&fvtv=8929Bavarian Nordics mpox- og koppevaccine opnår godkendelse i Schweiz 2024-03-13T12:29:21Z<![CDATA[KØBENHAVN, Danmark, 13. marts 2024 – Bavarian Nordic A/S (OMX: BAVA) meddelte i dag, at lægemiddelmyndighederne i Schweiz, Swissmedic, har godkendt JYNNEOS® (MVA-BN) til aktiv immunisering mod sygdom forårsaget af kopper, mpox og vacciniavirus hos voksne i alderen 18 år og opefter.]]>https://www.globenewswire.com/news-release/2024/03/12/2844822/0/en/Report-of-transactions-of-shares-and-related-securities-of-Bavarian-Nordic-by-persons-holding-managerial-responsibilities-and-or-persons-companies-closely-associated-with-such.html?f=22&fvtc=4&fvtv=8929Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such2024-03-12T16:30:00Z<![CDATA[COPENHAGEN, Denmark, March 12, 2024 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the Company’s shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such, which are hereby reported in accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523.]]>https://www.globenewswire.com/news-release/2024/03/12/2844822/0/da/Indberetning-af-ledende-medarbejdere-og-disses-n%C3%A6rtst%C3%A5endes-transaktioner-med-Bavarian-Nordic-aktier-og-tilknyttede-v%C3%A6rdipapirer.html?f=22&fvtc=4&fvtv=8929Indberetning af ledende medarbejdere og disses nærtståendes transaktioner med Bavarian Nordic aktier og tilknyttede værdipapirer 2024-03-12T16:30:00Z<![CDATA[KØBENHAVN, Danmark, 12. marts 2024 – Bavarian Nordic A/S (OMX: BAVA) har dags dato modtaget oplysninger om følgende transaktioner med selskabets aktie/tilknyttede værdipapirer, foretaget af ledende medarbejdere og/eller personer/firmaer der er nærtstående til disse, hvilke hermed offentliggøres i overensstemmelse med §19 i Europa Parlamentets og Rådets forordning (EU) nr. 596/2014 samt Kommissionens Gennemførelsesforordning (EU) nr. 2016/523.]]>https://www.globenewswire.com/news-release/2024/03/06/2841053/0/en/Report-of-transactions-of-shares-and-related-securities-of-Bavarian-Nordic-by-persons-holding-managerial-responsibilities-and-or-persons-companies-closely-associated-with-such.html?f=22&fvtc=4&fvtv=8929Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such2024-03-06T06:50:00Z<![CDATA[COPENHAGEN, Denmark, March 6, 2024 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the Company’s shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such, which are hereby reported in accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523.]]>https://www.globenewswire.com/news-release/2024/03/06/2841053/0/da/Indberetning-af-ledende-medarbejdere-og-disses-n%C3%A6rtst%C3%A5endes-transaktioner-med-Bavarian-Nordic-aktier-og-tilknyttede-v%C3%A6rdipapirer.html?f=22&fvtc=4&fvtv=8929Indberetning af ledende medarbejdere og disses nærtståendes transaktioner med Bavarian Nordic aktier og tilknyttede værdipapirer 2024-03-06T06:50:00Z<![CDATA[KØBENHAVN, Danmark, 6. marts 2024 – Bavarian Nordic A/S (OMX: BAVA) har dags dato modtaget oplysninger om følgende transaktioner med selskabets aktie/tilknyttede værdipapirer, foretaget af ledende medarbejdere og/eller personer/firmaer der er nærtstående til disse, hvilke hermed offentliggøres i overensstemmelse med §19 i Europa Parlamentets og Rådets forordning (EU) nr. 596/2014 samt Kommissionens Gennemførelsesforordning (EU) nr. 2016/523.]]>https://www.globenewswire.com/news-release/2024/03/06/2841051/0/da/Bavarian-Nordic-offentligg%C3%B8r-%C3%A5rsrapport-for-2023.html?f=22&fvtc=4&fvtv=8929Bavarian Nordic offentliggør årsrapport for 20232024-03-06T06:38:05Z<![CDATA[KØBENHAVN, Danmark, 6. marts 2024 – Bavarian Nordic A/S (OMX: BAVA) offentliggjorde i dag årsrapporten for 2023. De konsoliderede og reviderede finansielle resultater var i overensstemmelse med de foreløbige resultater, der blev udsendt den 21. februar 2024, og som oversteg de tidligere forventninger. Den fuldstændige rapport er vedhæftet som pdf-fil og kan desuden findes på selskabets hjemmeside www.bavarian-nordic.com.]]>https://www.globenewswire.com/news-release/2024/03/06/2841051/0/en/Bavarian-Nordic-Publishes-Annual-Report-2023.html?f=22&fvtc=4&fvtv=8929Bavarian Nordic Publishes Annual Report 20232024-03-06T06:38:05Z<![CDATA[COPENHAGEN, Denmark, March 6, 2024 – Bavarian Nordic A/S (OMX: BAVA) today published its Annual Report for 2023. The consolidated, audited results were in line with the preliminary results, announced on February 21, 2024, and exceeded prior guidance. The full report is attached as a PDF file and can be found on the Company's website, www.bavarian-nordic.com.]]>https://www.globenewswire.com/news-release/2024/02/23/2834229/0/en/Bavarian-Nordic-s-Chikungunya-Vaccine-Candidate-Granted-Accelerated-Assessment-by-European-Medicines-Agency.html?f=22&fvtc=4&fvtv=8929Bavarian Nordic’s Chikungunya Vaccine Candidate Granted Accelerated Assessment by European Medicines Agency2024-02-23T06:35:06Z<![CDATA[COPENHAGEN, Denmark, February 23, 2024 – Bavarian Nordic A/S (OMX: BAVA) (“the Company”) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted accelerated assessment for the upcoming Marketing Authorisation Application (MAA) for CHIKV VLP, the Company’s investigational chikungunya vaccine.]]>https://www.globenewswire.com/news-release/2024/02/23/2834229/0/da/Bavarian-Nordics-vaccinekandidat-mod-chikungunya-er-blevet-tildelt-fremskyndet-vurdering-af-Det-Europ%C3%A6iske-L%C3%A6gemiddelagentur.html?f=22&fvtc=4&fvtv=8929Bavarian Nordics vaccinekandidat mod chikungunya er blevet tildelt fremskyndet vurdering af Det Europæiske Lægemiddelagentur2024-02-23T06:35:06Z<![CDATA[KØBENHAVN, Danmark, 23. februar 2024 – Bavarian Nordic A/S (OMX: BAVA) meddelte i dag, at Udvalget for Humanmedicinske Lægemidler (Committee for Medicinal Products for Human Use (CHMP)) under Det Europæiske Lægemiddelagentur (EMA) har tildelt en fremskyndet vurdering (”accelerated assessment”) i forbindelse med den kommende ansøgning om markedsføringstilladelse for selskabets vaccinekandidat mod chikungunya, CHIKV VLP.]]>